Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy
Viruses · 03.04.2024 · 16 (4) · 561
DOI: 10.3390/v16040561 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 03.04.2024. Verfasst von María-Angélica Calderón-Peláez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Virology Group, Vice-Chancellor of Research, Universidad El Bosque, Bogotá 110121, Colombia. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad El Bosque.
Abstract (Originalsprache)
Gliomas account for approximately 75–80% of all malignant primary tumors in the central nervous system (CNS), with glioblastoma multiforme (GBM) considered the deadliest. Despite aggressive treatment involving a combination of chemotherapy, radiotherapy, and surgical intervention, patients with GBM have limited survival rates of 2 to 5 years, accompanied by a significant decline in their quality of life. In recent years, novel management strategies have emerged, such as immunotherapy, which includes the development of vaccines or T cells with chimeric antigen receptors, and oncolytic virotherapy (OVT), wherein wild type (WT) or genetically modified viruses are utilized to selectively lyse tumor cells. In vitro and in vivo studies have shown that the Zika virus (ZIKV) can infect glioma cells and induce a robust oncolytic activity. Consequently, interest in exploring this virus as a potential oncolytic virus (OV) for high-grade gliomas has surged. Given that ZIKV actively circulates in Colombia, evaluating its neurotropic and oncolytic capabilities holds considerable national and international importance, as it may emerge as an alternative for treating highly complex gliomas. Therefore, this literature review outlines the generalities of GBM, the factors determining ZIKV’s specific tropism for nervous tissue, and its oncolytic capacity. Additionally, we briefly present the progress in preclinical studies supporting the use of ZIKV as an OVT for gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virology Group, Vice-Chancellor of Research, Universidad El Bosque, Bogotá 110121, Colombia.
- Semillero ViroLogic 2020-2022, Virology Group, Vice-Chancellor of Research, Universidad El Bosque, Bogotá 110121, Colombia.
ORCID-Profile: María-Angélica Calderón-Peláez, Karol Gabriela González-Ipuz, Jaime E Castellanos
Förderung
- Universidad El Bosque
Zitieren
APA
Calderón-Peláez, M. A., Maradei Anaya, S. J., Bedoya-Rodríguez, I. J., González-Ipuz, K. G., Vera-Palacios, D., Buitrago, I. V., Castellanos, J. E., & Velandia-Romero, M. L. (2024). Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy. Viruses, 16(4), 561. https://doi.org/10.3390/v16040561
Vancouver
Calderón-Peláez MA, Maradei Anaya SJ, Bedoya-Rodríguez IJ, González-Ipuz KG, Vera-Palacios D, Buitrago IV, et al. Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy. Viruses. 2024;16(4):561. doi:10.3390/v16040561
BibTeX
@article{CaldernPelez2024,
author = {Calderón-Peláez, María-Angélica and Maradei Anaya, Silvia Juliana and Bedoya-Rodríguez, Ingrid Juliana and González-Ipuz, Karol Gabriela and Vera-Palacios, Daniela and Buitrago, Isabella Victoria and Castellanos, Jaime E and Velandia-Romero, Myriam L},
title = {Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy},
journal = {Viruses},
year = {2024},
volume = {16},
number = {4},
pages = {561},
doi = {10.3390/v16040561}
}
EUVIMED